key: cord-0751675-42zhqlq2
authors: Kurahashi, Yukiya; Furukawa, Koichi; Sutandhio, Silvia; Tjan, Lidya Handayani; Iwata, Sachiyo; Sano, Shigeru; Tohma, Yoshiki; Ohkita, Hiroyuki; Nakamura, Sachiko; Nishimura, Mitsuhiro; Arii, Jun; Kiriu, Tatsunori; Yamamoto, Masatsugu; Nagano, Tatsuya; Nishimura, Yoshihiro; Mori, Yasuko
title: Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination
date: 2022-05-05
journal: J Infect Dis
DOI: 10.1093/infdis/jiac178
sha: 42e0a9bd8b83d7079bc7951d497184f96a5e4701
doc_id: 751675
cord_uid: 42zhqlq2

The SARS-CoV-2 variant Omicron is now under investigation. We evaluated cross-neutralizing activity against Omicron in COVID-19 convalescent patients (n = 23) who had received two doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including Omicron, all became seropositive, and significant fold-increases (21.1–52.0) were seen regardless of the disease severity of subjects. Our findings thus demonstrate that two doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against Omicron.

In the efforts to control the spread of Omicron, a major challenge has been the low 9 seroconversion rates of cross-neutralizing antibody against Omicron in the sera of individuals 10 who are fully COVID-19-vaccinated [2] . In order to ensure the acquisition of sufficient cross-11 neutralizing activity in vaccinated individuals, several investigators [2-4] and our research group 12 [5] have recommended an mRNA vaccine booster dose, but as of this writing, data on the cross- Like most nations, Japan has been working to overcome the COVID-19 pandemic. Japan 16 has faced six COVID-19 waves (i.e., surges in new COVID cases followed by decreases) so far 17 (Supplementary Figure 1) [8]. The 1 st , 2 nd and 3 rd waves were shown to be caused by B. 

It is important to determine whether COVID-19 convalescent patients have cross-3 neutralizing activity against Omicron, because cross-neutralizing activity is the key to protection 4 against reinfection. We thus conducted the present study to evaluate the neutralizing activity 5 against the Delta and Omicron variants in the sera of COVID-19 convalescent patients. We also 6 evaluated the efficacy of two doses of mRNA vaccine by analyzing the neutralizing antibody 7 titer against Omicron in the same individuals. The SARS-CoV-2 Biken-2 (B2) strain and the D614G reference variant (accession no. in all analyses was set at P< .05. Statistical analyses were performed using STATA (ver. 14.2). 20 Sample size calculation was not performed. Table 5 ). The 17 seropositive rates of neutralizing antibodies were 97.5% for D614G, 87.5% for Delta, and 37.5% 18 for Omicron ( Figure 1A) . The GMTs of neutralizing antibodies were 18.7 against D614G, 7.7 19 against Delta, and 1.5 against Omicron (Supplementary Table 5 ). 20 The results of our comparison of the neutralizing antibody titers against D614G, Delta, and 21 Omicron in the patients with or without pneumonia in the 1 st -3 rd waves are provided in was only 59.1% and the GMT of neutralizing antibody against Omicron was 2.0, which was 3 identical to the cut-off point. 4 We next compared the neutralizing antibody titers against D614G, Alpha, or Delta with 5 those against Omicron in the patients with pneumonia in the 1 st -3 rd waves, the 4 th wave, and the 6 5 th wave ( Figure 1B) . We aligned the severity among the patient groups because there were no 7 sera samples from the 4 th wave or the 5 th wave patients without pneumonia. Significant fold- (Figures 2A and 2C , 22 Supplementary Figures 2A and 2B) . Table 6 ). Two doses of the vaccination were completed before 3 the sera were collected at 6-9 months post-onset. The GMTs of the neutralizing antibodies 4 against Alpha, Delta, and Omicron tended to decline from 1-3 months post-onset to 3-6 months 5 post-onset. After two doses of the vaccination, a significant fold-increase of the neutralizing 6 antibody titer against Omicron was also observed (Figures 2B and 2D) , indicating that the 7 neutralizing antibody against Omicron was boosted by the vaccination; however, the neutralizing 8 antibody titer against Omicron was significantly lower than those against the variants that were 9 suspected to have infected patients (D614G or Alpha) even after vaccination ( Figure 2C and 10 2D, Supplementary Figures 3C and 3D) .

The results of our analyses revealed that the neutralizing antibody titer against Omicron Our findings also demonstrated significant fold-decreases against Omicron relative to 21 D614G (×17.6), Alpha (×12.0), and Delta (×13.5) (Figure 1B) . Another study showed clear fold- . In the present study, the proportion of patients whose condition 1 was considered "critical" in the 5 th wave (75%) was much higher than those in the 1 st -3 rd waves 2 (9%) and the 4 th wave (58%), and this might have contributed to the lesser-than-expected fold-3 decrease against Omicron relative to Delta. Our results suggest that patients who have been 4 infected with any SARS-CoV-2 variant could possibly be re-infected with Omicron. 5 We also observed that the neutralizing antibody titer against Omicron increased after two Conflict of interest 5 The authors declare no conflicts of interest associated with this manuscript. This study has never been presented anywhere. The SARS-CoV-2 variants. Friedman's test and Bonferroni correction were performed to

compare the neutralizing antibody titers. Fold-increases of neutralizing antibody titer (12 months 1 post-onset relative to 6-9 months post-onset in A, and 6-9 months post-onset relative to 3-6 2 months post-onset in B) are shown above each graph. Fold-decreases of neutralizing antibody 3 titer against Delta and Omicron relative to D614G are indicated in C, and those against Delta and 4 Omicron relative to Alpha are indicated in D. Seropositive rates are shown below each graph. 5 The gray dashed line in each graph indicates the cut-off titer. One serum sample at 6-9 months waves and 4 th wave, respectively. 

Acquired neutralizing breadth against SARS-CoV-11 2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the vaccine 12 efficacy

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread 14 escape from neutralizing antibody responses

SARS-CoV-2 BA.1 variant is neutralized by 16 vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies

Japan: Coronavirus Pandemic Country Profile

Our World in Data. Coronavirus (COVID-19) Vaccinations

Early Differences in Cytokine Production by 26 Severity of Coronavirus Disease